The newest Market Talks overlaying the Health Care sector. Published solely on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

1500 ET – Intuitive Surgical continues to be grappling with a slowdown in demand for bariatric surgical procedures because of the rise of GLP-1 drugs like Ozempic, Chief Executive Gary Guthart tells an viewers on the JPMorgan Healthcare Conference. “The deceleration hasn’t stopped,” he says. “We’re still growing, but it’s decelerating.” What which means for the longterm outlook for bariatric weight-loss surgical procedures is unclear. Company executives have beforehand mentioned they count on the GLP-1-related slowdown to solely be brief time period. Shares rise 10%. (will.feuer@wsj.com; @WillFOIA)